cell_line |
mesothelioma cell line:Mero-82.CNhs13069.10853-111F7 |
165.7 |
0.894 |
cell_line |
malignant trichilemmal cyst cell line:DJM-1.CNhs10730.10412-106B7 |
165.3 |
0.904 |
cell_line |
mesothelioma cell line:ACC-MESO-4.CNhs11264.10494-107B8 |
164.0 |
0.911 |
cell_line |
gall bladder carcinoma cell line:TGBC14TKB.CNhs11256.10470-106I2 |
163.3 |
0.894 |
cell_line |
myeloma cell line:PCM6.CNhs11258.10474-106I6 |
126.1 |
0.91 |
cell_line |
squamous cell carcinoma cell line:EC-GI-10.CNhs11252.10463-106H4 |
113.9 |
0.902 |
cell_line |
epidermoid carcinoma cell line:A431.CNhs10743.10426-106D3 |
106.6 |
0.863 |
cell_line |
mesothelioma cell line:NCI-H2452.CNhs13064.10848-111F2 |
106.1 |
0.878 |
cell_line |
mesodermal tumor cell line:HIRS-BM.CNhs12191.10696-109G3 |
104.7 |
0.876 |
cell_line |
meningioma cell line:HKBMM.CNhs11945.10691-109F7 |
100.2 |
0.894 |
cell_line |
bile duct carcinoma cell line:TFK-1.CNhs11265.10496-107C1 |
90.9 |
0.877 |
cell_line |
anaplastic large cell lymphoma cell line:Ki-JK.CNhs11881.10795-110I3 |
90.6 |
0.838 |
cell_line |
pharyngeal carcinoma cell line:Detroit 562.CNhs11849.10723-110A3 |
86.1 |
0.869 |
cell_line |
papillotubular adenocarcinoma cell line:TGBC18TKB.CNhs10734.10417-106C3 |
76.3 |
0.842 |
cell_line |
large cell lung carcinoma cell line:IA-LM.CNhs11277.10509-107D5 |
73.5 |
0.847 |
cell_line |
mesothelioma cell line:ONE58.CNhs13075.10858-111G3 |
72.9 |
0.849 |
cell_line |
signet ring carcinoma cell line:Kato III.CNhs10753.10436-106E4 |
71.0 |
0.831 |
cell_line |
rectal cancer cell line:TT1TKB.CNhs11255.10469-106I1 |
70.6 |
0.798 |
cell_line |
acute myeloid leukemia (FAB M7) cell line:MKPL-1.CNhs11888.10802-111A1 |
69.1 |
0.755 |
cell_line |
transitional-cell carcinoma cell line:JMSU1.CNhs11261.10492-107B6 |
65.9 |
0.801 |
cell_line |
endometrial carcinoma cell line:OMC-2.CNhs11266.10497-107C2 |
63.8 |
0.812 |
cell_line |
small cell lung carcinoma cell line:WA-hT.CNhs11812.10562-108A4 |
62.3 |
0.771 |
cell_line |
pleomorphic hepatocellular carcinoma cell line:SNU-387.CNhs11933.10706-109H4 |
62.3 |
0.793 |
cell_line |
oral squamous cell carcinoma cell line:HSC-3.CNhs11717.10545-107H5 |
61.3 |
0.81 |
cell_line |
normal intestinal epithelial cell line:FHs 74 Int.CNhs11950.10812-111B2 |
61.2 |
0.844 |
cell_line |
plasma cell leukemia cell line:ARH-77.CNhs12807.10840-111E3 |
61.0 |
0.791 |
cell_line |
b cell line:RPMI1788.CNhs10744.10427-106D4 |
59.9 |
0.771 |
cell_line |
gastric adenocarcinoma cell line:MKN1.CNhs11737.10614-108G2 |
59.7 |
0.809 |
cell_line |
bile duct carcinoma cell line:HuCCT1.CNhs10750.10432-106D9 |
57.2 |
0.8 |
cell_line |
acute lymphoblastic leukemia (B-ALL) cell line:BALL-1.CNhs11251.10455-106G5 |
56.9 |
0.754 |
cell_line |
ductal cell carcinoma cell line:KLM-1.CNhs11100.10438-106E6 |
56.7 |
0.772 |
cell_line |
glioblastoma cell line:A172, tech_rep2.CNhs11248.10444-106F3 |
54.4 |
0.771 |
cell_line |
signet ring carcinoma cell line:NUGC-4.CNhs11270.10483-107A6 |
53.9 |
0.778 |
cell_line |
glioblastoma cell line:A172, tech_rep1.CNhs11185.10444-106F3 |
53.7 |
0.768 |
cell_line |
lung adenocarcinoma cell line:PC-14.CNhs10726.10408-106B3 |
53.6 |
0.733 |
cell_line |
glassy cell carcinoma cell line:HOKUG.CNhs11824.10688-109F4 |
52.8 |
0.743 |
cell_line |
mixed mullerian tumor cell line:HTMMT.CNhs11944.10689-109F5 |
52.4 |
0.801 |
cell_line |
mesothelioma cell line:ACC-MESO-1.CNhs11263.10493-107B7 |
51.8 |
0.795 |
cell_line |
squamous cell lung carcinoma cell line:EBC-1.CNhs11273.10486-107A9 |
50.2 |
0.785 |
cell_line |
NK T cell leukemia cell line:KHYG-1.CNhs11867.10777-110G3 |
49.4 |
0.731 |
cell_line |
leukemia, chronic megakaryoblastic cell line:MEG-01.CNhs11859.10752-110D5 |
47.3 |
0.721 |
cell_line |
myxofibrosarcoma cell line:MFH-ino.CNhs11729.10600-108E6 |
47.1 |
0.719 |
cell_line |
xeroderma pigentosum b cell line:XPL 17.CNhs11813.10563-108A5 |
46.8 |
0.76 |
cell_line |
oral squamous cell carcinoma cell line:SAS.CNhs11810.10544-107H4 |
46.7 |
0.74 |
cell_line |
squamous cell carcinoma cell line:T3M-5.CNhs11739.10616-108G4 |
44.8 |
0.757 |
cell_line |
gall bladder carcinoma cell line:TGBC2TKB.CNhs10733.10415-106C1 |
43.8 |
0.758 |
cell_line |
splenic lymphoma with villous lymphocytes cell line:SLVL.CNhs10741.10424-106D1 |
43.6 |
0.692 |
cell_line |
serous adenocarcinoma cell line:JHOS-2.CNhs11746.10639-108I9 |
43.5 |
0.74 |
cell_line |
cervical cancer cell line:ME-180.CNhs11289.10553-107I4 |
43.1 |
0.708 |
cell_line |
anaplastic carcinoma cell line:8305C.CNhs10745.10428-106D5 |
43.0 |
0.762 |
cell_line |
acute myeloid leukemia (FAB M2) cell line:NKM-1.CNhs11864.10765-110E9 |
42.9 |
0.689 |
cell_line |
embryonic kidney cell line: HEK293/SLAM infection, 24hr.CNhs11047.10451-106G1 |
41.9 |
0.632 |
cell_line |
tubular adenocarcinoma cell line:SUIT-2.CNhs11883.10797-110I5 |
40.7 |
0.773 |
cell_line |
adenocarcinoma cell line:IM95m.CNhs11882.10796-110I4 |
40.4 |
0.721 |
cell_line |
sacrococcigeal teratoma cell line:HTST.CNhs11829.10695-109G2 |
40.1 |
0.719 |
cell_line |
liposarcoma cell line:SW 872.CNhs11851.10726-110A6 |
39.4 |
0.702 |
cell_line |
renal cell carcinoma cell line:OS-RC-2.CNhs10729.10411-106B6 |
38.2 |
0.722 |
cell_line |
large cell non-keratinizing squamous carcinoma cell line:SKG-II-SF.CNhs11825.10692-109F8 |
37.6 |
0.669 |
cell_line |
acute myeloid leukemia (FAB M6) cell line:F-36E.CNhs13060.10836-111D8 |
36.9 |
0.594 |
cell_line |
gastric adenocarcinoma cell line:MKN45.CNhs11819.10612-108F9 |
36.9 |
0.695 |
cell_line |
B lymphoblastoid cell line: GM12878 ENCODE, biol_rep1.CNhs12331.10821-111C2 |
36.8 |
0.608 |
cell_line |
bone marrow stromal cell line:StromaNKtert.CNhs11931.10686-109F2 |
36.7 |
0.679 |
cell_line |
oral squamous cell carcinoma cell line:Ca9-22.CNhs10752.10434-106E2 |
36.6 |
0.682 |
cell_line |
bronchioalveolar carcinoma cell line:NCI-H358.CNhs11840.10709-109H7 |
36.4 |
0.665 |
cell_line |
osteosarcoma cell line:143B/TK^(-)neo^(R).CNhs11279.10510-107D6 |
35.9 |
0.613 |
cell_line |
thyroid carcinoma cell line:TCO-1.CNhs11872.10783-110G9 |
35.5 |
0.686 |
cell_line |
serous cystadenocarcinoma cell line:HTOA.CNhs11827.10693-109F9 |
34.6 |
0.683 |
cell_line |
B lymphoblastoid cell line: GM12878 ENCODE, biol_rep3.CNhs12333.10823-111C4 |
34.5 |
0.593 |
cell_line |
giant cell carcinoma cell line:Lu99B.CNhs10751.10433-106E1 |
33.9 |
0.664 |
cell_line |
bronchogenic carcinoma cell line:ChaGo-K-1.CNhs11841.10710-109H8 |
33.6 |
0.648 |
cell_line |
mucinous cystadenocarcinoma cell line:MCAS.CNhs11873.10784-110H1 |
33.4 |
0.631 |
cell_line |
mesothelioma cell line:Mero-41.CNhs13067.10851-111F5 |
33.1 |
0.686 |
cell_line |
papillary adenocarcinoma cell line:8505C.CNhs11716.10437-106E5 |
32.9 |
0.678 |
cell_line |
acute myeloid leukemia (FAB M2) cell line:Kasumi-6.CNhs13052.10792-110H9 |
32.9 |
0.625 |
cell_line |
acantholytic squamous carcinoma cell line:HCC1806.CNhs11844.10717-109I6 |
32.6 |
0.638 |
cell_line |
acute myeloid leukemia (FAB M0) cell line:KG-1.CNhs13053.10827-111C8 |
32.1 |
0.586 |
cell_line |
myelodysplastic syndrome cell line:SKM-1.CNhs11934.10772-110F7 |
32.1 |
0.592 |
cell_line |
mesothelioma cell line:Mero-25.CNhs13066.10850-111F4 |
32.1 |
0.67 |
cell_line |
B lymphoblastoid cell line: GM12878 ENCODE, biol_rep2.CNhs12332.10822-111C3 |
31.2 |
0.572 |
cell_line |
cord blood derived cell line:COBL-a 24h infection(-C).CNhs11049.10452-106G2 |
31.1 |
0.537 |
cell_line |
acute myeloid leukemia (FAB M6) cell line:EEB.CNhs13059.10835-111D7 |
30.9 |
0.572 |
cell_line |
Ewing's sarcoma cell line:Hs 863.T.CNhs11836.1070 |